115 related articles for article (PubMed ID: 35617527)
1. TCF3 protein was highly expressed in pediatric Burkitt lymphoma and predicts poor prognosis: a single-center study.
Man J; Wang H; Qian X; Chen L; Ma Y; Qian M; Zhai X
Leuk Lymphoma; 2022 Oct; 63(10):2453-2460. PubMed ID: 35617527
[TBL] [Abstract][Full Text] [Related]
2. Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.
Rohde M; Bonn BR; Zimmermann M; Lange J; Möricke A; Klapper W; Oschlies I; Szczepanowski M; Nagel I; Schrappe M; ; ; Loeffler M; Siebert R; Reiter A; Burkhardt B
Haematologica; 2017 Jun; 102(6):1091-1098. PubMed ID: 28209658
[TBL] [Abstract][Full Text] [Related]
3. [Expression of TCF3 in Burkitt's Lymphoma and Its Proliferative Effect and Prognostic Significance].
Dong LH; Huang JJ; Liu J; Gao X; DU JW; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1435-1439. PubMed ID: 36208246
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
[TBL] [Abstract][Full Text] [Related]
5. [Expression of p-AKT and p-mTOR in pediatric Burkitt lymphoma and their correlation with prognosis].
Man J; Chen L; Zhai XW; Ma YY; Wang HS; Qian XW; Feng JY; Zhao J; Cao P; Lu FJ
Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):156-161. PubMed ID: 32074729
[No Abstract] [Full Text] [Related]
6. [Clinical Efficacy and Prognostic Factors of Newly Diagnosed Children[JP] with Burkitt Lymphoma Treated by High-Dose and Short-Course Modified LMB Regimen ± Rituximab].
Wang BT; Dang HB; Wei YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):529-534. PubMed ID: 32319391
[TBL] [Abstract][Full Text] [Related]
7. [Clinical and prognostic analysis of 186 children with Burkitt's lymphoma].
Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
Zhonghua Er Ke Za Zhi; 2018 Aug; 56(8):605-610. PubMed ID: 30078243
[No Abstract] [Full Text] [Related]
8. [Clinical analysis of a modified LMB89 Group C regimen in the treatment of pediatric high-risk Burkitt lymphoma].
Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):633-638. PubMed ID: 31495128
[No Abstract] [Full Text] [Related]
9. Transcription factor 3 (TCF3) combined with histone deacetylase 3 (HDAC3) down-regulates microRNA-101 to promote Burkitt lymphoma cell proliferation and inhibit apoptosis.
Dong L; Huang J; Zu P; Liu J; Gao X; Du J; Li Y
Bioengineered; 2021 Dec; 12(1):7995-8005. PubMed ID: 34658308
[TBL] [Abstract][Full Text] [Related]
10. [Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma].
Zhang M; Wu P; Duan YL; Jin L; Yang J; Huang S; Liu Y; Hu B; Zhai XW; Wang HS; Fu Y; Li F; Yang XM; Liu AS; Qin S; Yuan XJ; Dong YS; Liu W; Zhou JW; Zhang LP; Jia YP; Wang J; Qu LJ; Dai YP; Guan GT; Sun LR; Jiang J; Liu R; Jin RM; Wang ZJ; Wang XG; Zhang BX; Chen KL; Zhuang SQ; Zhang J; Zhou CJ; Gao ZF; Zheng MC; Zhang Y
Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1011-1018. PubMed ID: 36207847
[No Abstract] [Full Text] [Related]
11. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
Forero-Castro M; Robledo C; Lumbreras E; Benito R; Hernández-Sánchez JM; Hernández-Sánchez M; García JL; Corchete-Sánchez LA; Tormo M; Barba P; Menárguez J; Ribera J; Grande C; Escoda L; Olivier C; Carrillo E; García de Coca A; Ribera JM; Hernández-Rivas JM
Br J Haematol; 2016 Feb; 172(3):428-38. PubMed ID: 26567765
[TBL] [Abstract][Full Text] [Related]
12. Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08.
Lones MA; Sanger WG; Le Beau MM; Heerema NA; Sposto R; Perkins SL; Buckley J; Kadin ME; Kjeldsberg CR; Meadows A; Siegel S; Finlay J; Bergeron S; Cairo MS;
J Pediatr Hematol Oncol; 2004 Mar; 26(3):169-78. PubMed ID: 15125609
[TBL] [Abstract][Full Text] [Related]
13. Burkitt lymphoma-related
Yamazaki T; Liu L; Conlon EG; Manley JL
RNA Biol; 2020 Oct; 17(10):1383-1390. PubMed ID: 32449435
[TBL] [Abstract][Full Text] [Related]
14. Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma.
Valencia-Hipόlito A; Hernández-Atenógenes M; Vega GG; Maldonado-Valenzuela A; Ramon G; Mayani H; Peña Alonso Y; Martinez-Maza O; Méndez-Tenorio A; Huerta-Yepez S; Bonavida B; Vega MI
Leuk Lymphoma; 2014 Aug; 55(8):1806-14. PubMed ID: 24067139
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Results of the Risk-Stratified Treatment of TCF3-PBX1-Positive Pediatric Acute Lymphoblastic Leukemia in China.
Wang Y; Xue YJ; Lu AD; Jia YP; Zuo YX; Zhang LP
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e137-e144. PubMed ID: 33221150
[TBL] [Abstract][Full Text] [Related]
16. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Roschewski M; Dunleavy K; Abramson JS; Powell BL; Link BK; Patel P; Bierman PJ; Jagadeesh D; Mitsuyasu RT; Peace D; Watson PR; Hanna WT; Melani C; Lucas AN; Steinberg SM; Pittaluga S; Jaffe ES; Friedberg JW; Kahl BS; Little RF; Bartlett NL; Fanale MA; Noy A; Wilson WH
J Clin Oncol; 2020 Aug; 38(22):2519-2529. PubMed ID: 32453640
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma].
Zhang YH; Duan YL; Yang J; Jin L; Zhou CJ; Gao ZF
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):209-14. PubMed ID: 19099711
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols.
Felice MS; Gallego MS; Alonso CN; Alfaro EM; Guitter MR; Bernasconi AR; Rubio PL; Zubizarreta PA; Rossi JG
Leuk Lymphoma; 2011 Jul; 52(7):1215-21. PubMed ID: 21534874
[TBL] [Abstract][Full Text] [Related]
19. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
[TBL] [Abstract][Full Text] [Related]
20. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
Wilke AC; Doebele C; Zindel A; Lee KS; Rieke SA; Ceribelli M; Comoglio F; Phelan JD; Wang JQ; Pikman Y; Jahn D; Häupl B; Schneider C; Scheich S; Tosto FA; Bohnenberger H; Stauder P; Schnütgen F; Slabicki M; Coulibaly ZA; Wolf S; Bojarczuk K; Chapuy B; Brandts CH; Stroebel P; Lewis CA; Engelke M; Xu X; Kim H; Dang TH; Schmitz R; Hodson DJ; Stegmaier K; Urlaub H; Serve H; Schmitt CA; Kreuz F; Knittel G; Rabinowitz JD; Reinhardt HC; Vander Heiden MG; Thomas C; Staudt LM; Zenz T; Oellerich T
Blood; 2022 Jan; 139(4):538-553. PubMed ID: 34624079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
